Limitations of the epcoritamab vs odronextamab comparative analysis.

Kim TM, Kamat SA

DOI: 10.1182/bloodadvances.2025018226
Published: 2026 Mar 10
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018226,
  title = {Limitations of the epcoritamab vs odronextamab comparative analysis.},
  author = {Kim TM and Kamat SA},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2025018226},
  url = {https://doi.org/10.1182/bloodadvances.2025018226}
}

RIS

TY  - JOUR
TI  - Limitations of the epcoritamab vs odronextamab comparative analysis.
AU  - Kim TM
AU  - Kamat SA
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2025018226
UR  - https://doi.org/10.1182/bloodadvances.2025018226
ER  -

APA

TM, K., & SA, K. (2026). Limitations of the epcoritamab vs odronextamab comparative analysis.. Blood advances. https://doi.org/10.1182/bloodadvances.2025018226

Source records

pubmed · retrieved 2026-09-26T01:38:11.595Z